On June 22, 2026, CEO Luis C. Pena sold 7,438 shares, netting approximately 168,916, while CSO Jeegar Patel exercised options and sold shares at 22.50 each. These transactions occurred under Rule 10b5-1 plans established in early March. However, the subsequent failure of the EVO756 trial—a treatment for chronic spontaneous urticaria—was disclosed just one week later, triggering a sharp decline in investor value.
Evommune Executives Under Scrutiny Following Timely Stock Sales
Days before announcing that its lead drug candidate, EVO756, failed a critical Phase 2b clinical trial, Evommune executives offloaded thousands of shares. The timing of these transactions, which preceded a 38% collapse in the company's stock price, has prompted an investigation by the law firm Levi & Korsinsky, LLP.
Legal representatives are scrutinizing Form 144 filings submitted by the insiders, which included declarations that the sellers possessed no material adverse information regarding the company's operations. Levi & Korsinsky is now evaluating whether these representations accurately reflected the state of internal trial data at the time. Shareholders who sustained losses are being urged to review their trading records as the firm assesses potential securities law violations.
Comments (0)
No comments yet. Be the first!